RIPK2-IN-8

RIPK2-IN-8 is an orally active and highly selective RIPK2 inhibitor (IC50 = 11 nM) . RIPK2-IN-8 is highly selective for RIPK2 over RIPK1 (IC50 > 30,000 nM) and has a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM) . RIPK2-IN-8 inhibits the NOD2-RIPK2 signaling pathway and the expression of the inflammatory cytokines IL-6 and TNFα, thereby exerting anti-inflammatory effects. RIPK2-IN-8 has demonstrated anti-inflammatory and hepatoprotective effects in an acute liver injury (ALI) model and can be used in ALI research[1].

Product Specifications

CAS Number

[3036254-29-9]

UNSPSC

12352005

Target

Interleukin Related; NF-κB; p38 MAPK; RIP kinase

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

CCC(NC1CCC(C2=CC(N=CN=C3NC4=CC(N=CS5)=C5C=C4F)=C3S2)=CC1)=O

Molecular Formula

C22H20FN5OS2

Molecular Weight

453.56

References & Citations

[1]Zhao H, et al. Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy. Eur J Med Chem. 2025 Jul 5;297:117932.|[2]Zhao H, et al. Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy. Eur J Med Chem. 2025 Jul 5;297:117932.